Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); B-Mod Still Has A Shot

Article Stock Quotes (1) Comments (0)

Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $3.00 (from $6.00).

Analyst, Ritu Baral, said, "Reiterate rating, lowering target to $3 on blisibimod’s (B-mod) continued, but now delayed, clinical/market potential in lupus. We expect B-mod, ANTH's lupus BAFF peptibody, will start Ph3 in H1/13. ANTH may start Ph2 B-mod trials in other lupus-related disorders in 2013 too. Our $3 pNPV target is on modestly lower peak sales and delayed approval, noting a significant near-term financing risk."

For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.

Shares of Anthera Pharma closed at $0.74 yesterday, with a 52 week range of $0.60-$8.63.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Deutsche Bank Raises PT on Access Midstream Partners (ACMP) to $57
• Cisco (CSCO) PT Raised to $26.50 at Nomura

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?